AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02522780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesalamine
Description: Pharmaceutical form: Granules in sachet; Route of administration: Oral use
Study NCT02522780 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: Granules in sachet; Route of administration: Oral use
Study NCT01715649 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient education, self-monitoring of blood glucose and remote patient monitoring of blood glucose
Description: In the intervention arm you will test your blood glucose 2 times a day (before and after a meal, activity or other event) using the glucose meter provided to you for use in this study and connect it to the Telehealth Unit. Every week the study team will review your blood glucose levels through the remote patient monitoring secure portal and send you a reminder through the Telehealth Unit with suggestions based on your blood glucose patterns. Once every month a study nurse will call you to review your blood glucose goals and discuss how you may be able to make changes in your health behaviors to improve your blood glucose levels. The study team will work with you to help you make changes to your behaviors that may improve your blood glucose.
Study NCT01513395 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interval bladder emptying
Description: Participants randomized to the Interval arm (cervical assessment 15 minutes or more after voiding) will be notified of their allocation and asked to immediately use the rest room and attempt to void completely. A synchronized clock will be located in this restroom, and each participant will be asked to note the time that she completes voiding. This will be confirmed by the research staff by noting the time the participant enters and exits the restroom. The participant will return to the waiting room or ultrasound room. Any indicated trans-abdominal ultrasound imaging will be performed, and preparations will be made for the vaginal ultrasound. The participant will be asked not to void prior to the vaginal ultrasound. Cervical assessment will take place at a minimum of 15 minutes from voiding time.
Study NCT00526162 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bi-ventricular Implantable Cardioverter Defibrillator
Description: Implantation of a Bi-ventricular Implantable Cardioverter Defibrillator
Study NCT00002784 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET photon therapy
Description: radiation therapy to the conserved breast is mandatory, to be carried out according to the prospectively defined guidelines of each participating institution; either after all chemotherapy or integrated into CMF as agreed per institution. Radiotherapy to the chest wall following mastectomy is optional according to the prospectively defined guidelines of each participating institution.
Study NCT00002784 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: low-LET photon therapy
Description: radiation therapy to the conserved breast is mandatory, to be carried out according to the prospectively defined guidelines of each participating institution; either after all chemotherapy or integrated into CMF as agreed per institution. Radiotherapy to the chest wall following mastectomy is optional according to the prospectively defined guidelines of each participating institution.
Study NCT01230034 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramipril
Description: pill, 5 and 10 mg/day, od, 24 weeks
Study NCT01230034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imidapril
Description: pill, 10 and 20 mg/day, od, 24 weeks
Study NCT01983670 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Temporal electrical stimulation
Study NCT03786354 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Undergo 3DCRT
Study NCT03786354 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT
Study NCT00875082 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast
Description: Montelukast, chewing tablets 5mg, once daily, 8 weeks
Study NCT03841708 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pleth variability index
Description: The utility of a early goal directed therapy will be evaluate by the pleth variability index (PVI). If above>13% in a well sedated patients perfectly synchronized with the ventilator providing at least 6ml/kg of ideal body weight, a fluid challeng with 10ml/kg of NaCl 0,9% will be administrated. Patient will be constantly re-assessed until the hemodynamic goals of a mean arterial pressure above 65 mmHg, a capillary refill time below 3 seconds, a decreasing trend on lactates and a urinary output above 0.5/ml/kg/h will be achieved. The second fluid challenge will always be performed with 100 ml of albumin 20%. The third fluid challenge if necessary will be performed with 10 ml/kg of NaCl 0.9%.
Study NCT00875082 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo chewing tablets once daily, plus inhaled short acting beta2 agonist as needed, 8 weeks
Study NCT03841708 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Standard non invasive monitoring
Description: In the control group patients will be hemodynamically resuscitated in the early phases after ROSC based on standard non invasive monitoring such as SatO2, EtCO2, non invasive blood pressure and continuous ECG. If deemed necessary by the treating physician a fluid challenge of 10ml/kg of NaCl 0,9% will be administrated. Patient will be constantly re-assessed until the hemodynamic goals of a mean arterial pressure above 65 mmHg, a capillary refill time below 3 seconds, a decreasing trend on lactates and a urinary output above 0.5/ml/kg/h will be achieved. The second fluid challenge will always be performed with 100 ml of albumin 20%. The third fluid challenge if necessary will be performed with 10 ml/kg of NaCl 0.9%.
Study NCT03743922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calciferol
Description: calciferol capsule
Study NCT03743922 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo capsule
Study NCT03869853 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Entrepreneurial stimulation and integrated education
Description: one month cycle of stimulation of business with integrated education on nutrition, health, and gender empowerment
Study NCT03869853 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: control
Description: no intervention
Study NCT03795974 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MNC
Description: Hematopoietic stem cells derived from allogenic umbilical cord
Study NCT03795974 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MNC
Description: Hematopoietic stem cells derived from allogenic umbilical cord
Study NCT03795974 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSC
Description: Mesenchymal cells derived from allogenic umbilical cord
Study NCT03795974 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MSC
Description: Mesenchymal cells derived from allogenic umbilical cord
Study NCT03795974 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: control group without injection and appearance simulating lumbar puncture without awareness of the patients and evaluators , but rehabilitation continued .
Study NCT06232161 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Red-light therapy device
Description: Red-light therapy was performed with a low-intensity laser (LD-A, Jilin LD Optoelectronics Technology, Jilin, China) with an irradiance of 0.35 ± 0.02 mW/cm2, a wavelength of 650 nm ± 10 nm, and illumination of approximately 400 lux on average.
Study NCT06232161 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Spectacles
Description: Single focus spectacles, that is to say, wearing glasseses with minus power lens
Study NCT06232161 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectacles
Description: Single focus spectacles, that is to say, wearing glasseses with minus power lens
Study NCT01188317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aleglitazar
Description: repeated daily doses
Study NCT01188317 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: repeated daily doses
Study NCT01188317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibuprofen
Description: repeated daily doses
Study NCT01188317 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ibuprofen
Description: repeated daily doses
Study NCT01734811 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological vaccine
Description: daily spray (2 puff of 100 µL) for six months
Study NCT01734811 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Biological vaccine
Description: daily spray (2 puff of 100 µL) for six months
Study NCT03918135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: 1000 mg of paracetamol (parol 10mg/ml Mefar, Turkey) intravenous (IV) was given 100 patients~Other Names:~* Perfalgan~* Paracerol
Study NCT03918135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: 400mg of ibuprofen(intrafen 400mg/4ml Gen ilaç sanayi, Turkey) intravenous (IV) was given 100 patients~Other Names:~Dorifen
Study NCT03118752 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collaborative Care
Description: The CC intervention will use a novel three-pronged approach to these high-risk patients. Care managers will provide centralized care coordination and specific interventions targeting: (1) the psychiatric disorders, (2) cardiac health behaviors, and (3) the cardiac illness.
Study NCT04415268 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Surpervised exercise program: Includes a concurrent exercise intervention (strength training and aerobic training), 3 days a week, 60 minutes sessions.
Study NCT04415268 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unsupervised exercise
Description: Unsupervised exercise program: The same exercise program learned during the supervised phase will be practiced at home.
Study NCT04415268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CFTR Modulators
Description: Standard of care: Lumacaftor with Ivacaftor or Tezacaftor combined with Ivacaftor.~For children between 6 and 11 years of age, Lumacaftor 400 mg combined with Ivacaftor 500 mg in total per day, divided into 2 doses per day; for those over 11 years of age, Tezacaftor 100 mg combined with Ivacaftor 150 mg in the morning, adding a dose of Ivacaftor 150 mg at night.~https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000833-37/ES
Study NCT03857724 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: prolapse surgery
Description: prolapse surgery
Study NCT04781244 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EndWarts® FREEZE
Description: EndWarts® FREEZE is an alternative home cryotherapy device. Patients don't have to go to the hospital to receive treatment for their wart.
Study NCT04781244 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Liquid nitrogen
Description: Liquid nitrogen is a conventional cryotherapy treatment for cutaneous wart performed by physician at the hospital.
Study NCT05025033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 antibody, paclitaxel or irinotecan, Apatinib mesylate
Description: PD-1 antibody 200mg intravenous drip every 3 weeks; Apatinib 250mg/day; Chemotherapy: Irinotecan 150mg/m2, intravenous drip every 2 weeks, or Paclitaxel 150mg/m2, intravenous drip, once every 3 weeks.
Study NCT01112891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 10 ug/day Vitamin D as part of standard pre-natal vitamin supplement, taken from 18 weeks gestation to 6 months postpartum.
Study NCT01112891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: 25 ug/day Vitamin D as part of standard pre-natal vitamin supplement, taken from 18 weeks gestation to 6 months postpartum.
Study NCT03418779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The Yi-Qi-Qing-Jie herbal compound
Description: The compounds are blends of individual herbal extracts from YQF (consisting of Astragalus membranaceus, Saposhnikovia divaricata (turcz.) Schischk, Flos lonicerae, Angelica sinensis, Dioscorea nipponica, Hedyotis diffusa Willd, rhubarb, Spatholobus suberectus, with the effect of reinforcing Qi and activating blood, clearing away heat and poison, dissolving dampness and downbearing turbid) dissolved in 150 ml boiled water and taken orally twice a day for the duration of the treatment and follow-up phases.
Study NCT03418779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunosuppressants
Description: Immunosuppression therapy comprises oral prednisolone (0.5-0.8 mg/kg/day; exact dose decided by the investigator, maximum dose not exceeding 60 mg/day) for 8 weeks, then tapered by 5-10 mg/day every 4 weeks, with a total treatment period of 24-32 weeks. Participants with persistent proteinuria ≥ 1 g/day after 8 weeks of corticosteroid monotherapy will receive 0.8-1.0 g of intravenous cyclophosphamide (CTX) every 4 weeks, total dose of not exceeding 8 g (exact dose decided by the site investigator). If severe CTX-related adverse events occur, such as alanine transaminase (ALT) exceeding the upper limit of two times, infections requiring hospitalization, granulocytes \< 3.0 × 109/L and platelets \< 50.0 × 109/L, CTX will stop being administered, symptoms will be treated, and adverse events recorded. Also, the frequency of detection will be increased to once every 2 weeks and the affected participant will be withdrawn if persistent infection or myelosuppression occurs.
Study NCT03418779 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optimized Supportive Care
Description: The optimized supportive care included:~1. Lifestyle: low-salt, restricted protein dietary with sufficient calorie supply, smoking cessation, moderate alcohol consumption and keeping a healthy weight~2. The use of renin-angiotensin system blockade: lowering blood pressure to a target below 135/85 mmHg, during which treatment was adjusted to ensure that patients were receiving the maximum labelled or tolerated dose of RAS blockade~3. Patients with Diabetes Mellitus received insulin or oral hypoglycemic agents to achieve HbA1c≤ 7.0%~4. Received uricosuric agents or xanthine oxidase inhibitors as necessary to achieve serum uric acid \<6 mg/dL in female, \<7 mg/dL in male
Study NCT03418779 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yi-Qi-Qing-Jie herbal compound placebo
Description: Patients will receive Yi-Qi-Qing-Jie herbal compound placebo instead for the duration of the treatment and follow-up phases. The major component of the placebo is malt dextrin which looks, smells and tastes like YQF compound, and it comes in packaging with a similar appearance to YQF compound; it is also dissolved in 150 ml boiled water and taken orally twice a day.
Study NCT01360281 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular Electrical Stimulation
Study NCT01360281 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ECR
Description: Resisted exercises
Study NCT01291433 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pentoxifylline placebo
Description: Placebo for pentoxifylline 400 mg, 1 cp twice a day (7d/7)
Study NCT00710723 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: vitrification
Description: Vitrification using Hemi-straw carrier system.
Study NCT00561574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmirtazapine
Description: One tablet daily
Study NCT01433861 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopy-assisted gastrectomy
Description: Laparoscopy-assisted proximal gastrectomy versus Laparoscopy-assisted total gastrectomy
Study NCT01291433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: Pentoxifylline 400 mg: 1 cp twice a day (7d/7)
Study NCT01291433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocopherol acetate
Description: Tocopherol alpha-acetate, 500 mg: 1 capsule twice a day (7d/7)
Study NCT02675855 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GrafixPRIME®
Description: Human tissue, Wound cover, Application of a non-adherent dressing, a moisture retentive dressing, and a secondary dressing.
Study NCT02675855 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dressing Application
Description: Wound cover, Application of a non-adherent dressing, a moisture retentive dressing, and a secondary dressing.
Study NCT02675855 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Off-loading (walking boot)
Description: Patients will be fitted for an off-loading device (walking boot) and agree to comply with use of the device during the course of the study
Study NCT02675855 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Off-loading (walking boot)
Description: Patients will be fitted for an off-loading device (walking boot) and agree to comply with use of the device during the course of the study
Study NCT02288858 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Viviscal Oral Supplement Tablets
Description: Tablet (512 mg)
Study NCT02288858 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Viviscal Oral Supplement Tablets
Description: Tablet (512 mg)
Study NCT01291433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clodronic Acid
Description: Clodronate disodium (clodronic acid) 800 mg: 2 cp per day, 5d/7 (from monday to friday)
Study NCT01291433 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tocopherol placebo
Description: Placebo for Tocopherol alpha-acetate, 500 mg: 1 capsule twice a day (7d/7)
Study NCT01291433 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clodronate placebo
Description: Placebo for clodronate disodium (clodronic acid) 800 mg: 2 cp per day, 5d/7 (from monday to friday)
Study NCT01143077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurasidone HCl
Description: Lurasidone tablets, 40 mg/daily, 80 mg/daily, 120 mg/daily for 6 weeks
Study NCT01641861 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Papacarie®
Description: Papacarie® is chemo-mechanical method for caries removal
Study NCT01641861 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional method
Description: caries removal by using rotary instrument.
Study NCT04214860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APR-246
Description: APR-246 4.5 g/day
Study NCT00730197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol Sulfate Extended-Release Tablets 8 mg
Description: 8mg, single dose fed
Study NCT00730197 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VoSpire® ER Tablets 8 mg
Description: 8mg, single dose fed
Study NCT04214860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax 400 mg once daily
Study NCT04214860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Subcutaneous injection, or intravenous infusion
Study NCT02228603 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: high-intensity exercise training
Study NCT02228603 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: web-based follow-up program
Study NCT02228603 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: usual care
Study NCT01767857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xilonix
Description: Xilonix is a True Human Monoclonal Antibody targeting Interleukin 1 alpha, and is administered intravenously every 2 weeks with best supportive care until clinical or radiographic progression.
Study NCT01767857 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo plus best supportive care will be administered intravenously every 2 weeks until clinical or radiographic progression.
Study NCT01421459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2963016
Description: Administered subcutaneously
Study NCT01421459 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lantus
Description: Administered subcutaneously
Study NCT01421459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OAMs
Description: Administered orally
Study NCT02325310 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Combined measles-mumps-rubella (MMR) vaccine - PRIORIX®
Description: One dose of 0.5 mL vaccine will be administered (intra-muscularly or subcutaneous) in post-partum (before the exit of the maternity) during visit V0. A second dose will be administered at week 8(+/-15 days) during visit V1.
Study NCT03568084 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MEFAP
Description: multicomponent physical activity program (MEFAP) with 12 weekly sessions of an hour and a half which includes 1) briefing 2) exercises for improving aerobic resistance, muscle strength, proprioception-balance and flexibility and 3) delivery of exercise chart to do at home (two times per week).
Study NCT03568084 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control usual practice
Description: Individuals allocated to this arm, will be look after as usual in their health Centers.
Study NCT03568084 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: control usual practice
Description: Individuals allocated to this arm, will be look after as usual in their health Centers.